多中心深度学习合成CT用于肛门直肠癌MR-only放疗计划
本研究基于两个中心90例肛门直肠癌患者的T2-SPACE MR和CT扫描,训练并测试了一种采用focal loss的条件生成对抗网络(cGAN)模型生成合成CT(sCT)。结果显示CT与sCT之间PTV D95%平均剂量差异为0.1%,所有 gamma 指数(1%/1 mm阈值)测量值均>99.0%,LME模型表明模态、癌症部位、性别和中心的影响在临床上不显著。
要点
- cGAN生成的sCT在肛门直肠癌患者中剂量学准确,PTV D95%平均差异仅0.1%。
- 所有gamma指数(1%/1 mm)测量值均超过99.0%,验证了sCT的剂量学精度。
- 多中心、T2-SPACE序列及性别和癌症部位对sCT质量的影响在临床上不显著。
核心结论
- 采用focal loss的cGAN模型使用多中心T2-SPACE MR序列可生成可泛化且剂量学准确的sCT,适用于肛门直肠癌MR-only放疗计划。
研究设计与样本
- 多中心研究,收集两个中心90例肛门直肠癌患者的放疗体位CT和T2-SPACE MR扫描。
- cGAN模型采用focal loss函数训练,训练集46例、测试集44例CT-MR肛门直肠数据集,通过可变形配准配对。
- 在CT上创建VMAT计划并在sCT上重新计算,评估剂量差异和gamma指数,并用线性混合效应模型评估中心、性别和癌症部位的影响。
主要发现
- CT与sCT之间PTV D95%平均剂量差异为0.1%(范围:-0.5%至0.7%)。
- 所有gamma指数(1%/1 mm阈值)测量值均>99.0%。
- LME模型发现模态、癌症部位、性别和中心的影响在临床上不显著(效应范围:-0.4%至0.3%)。
- 所有OAR约束的平均剂量差异为0.1%。
关键数值与推荐
- PTV D95%平均剂量差异0.1%(范围:-0.5%至0.7%)。
- gamma指数(1%/1 mm阈值)所有测量值>99.0%。
- OAR约束平均剂量差异0.1%。
- LME模型效应范围:-0.4%至0.3%,临床不显著。
临床怎么用
- 该cGAN模型生成的sCT可用于肛门直肠癌MR-only放疗计划的剂量学评估,支持临床实施前的全面剂量分析。
- 多中心T2-SPACE MR序列生成的sCT具有泛化性,性别和癌症部位不影响sCT质量,可简化临床工作流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Comprehensive dosimetric analysis is required prior to the clinical implementation of pelvic MR-only sites, other than prostate, due to the limited number of site specific synthetic-CT (sCT) dosimetric assessments in the literature. This study aims to provide a comprehensive assessment of a deep learning-based, conditional generative adversarial network (cGAN) model for a large ano-rectal cancer cohort. The following challenges were investigated; T2-SPACE MR sequences, patient data from multiple centres and the impact of sex and cancer site on sCT quality. METHOD: RT treatment position CT and T2-SPACE MR scans, from two centres, were collected for 90 ano-rectal patients. A cGAN model trained using a focal loss function, was trained and tested on 46 and 44 CT-MR ano-rectal datasets, paired using deformable registration, respectively. VMAT plans were created on CT and recalculated on sCT. Dose differences and gamma indices assessed sCT dosimetric accuracy. A linear mixed effect (LME) model assessed the impact of centre, sex and cancer site. RESULTS: A mean PTV D95% dose difference of 0.1% (range: -0.5% to 0.7%) was found between CT and sCT. All gamma index (1%/1 mm threshold) measurements were >99.0%. The LME model found the impact of modality, cancer site, sex and centre was clinically insignificant (effect ranges: -0.4% and 0.3%). The mean dose difference for all OAR constraints was 0.1%. CONCLUSION: Focal loss cGAN models using T2-SPACE MR sequences from multiple centres can produce generalisable, dosimetrically accurate sCTs for ano-rectal cancers.
引用
- Bird D, Nix MG, McCallum H, et al. Multicentre, deep learning, synthetic-CT generation for ano-rectal MR-only radiotherapy treatment planning. Radiother Oncol. 2020. PMID: 33264638. doi:10.1016/j.radonc.2020.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。